Know Cancer

forgot password

The Role Of Fructose and Uric Acid In the Development of Obesity and Metabolic Syndrome

18 Years
60 Years
Not Enrolling
Overweight and Obesity, Metabolic Syndrome, Hyperuricemia

Thank you

Trial Information

The Role Of Fructose and Uric Acid In the Development of Obesity and Metabolic Syndrome

Overweight and obesity are now considered a growing public health problem in Mexico and
worldwide. This epidemic has been attributed to dietary fructose consumption. Although
experimental models have demonstrated a role of fructose in the development of obesity,
metabolic syndrome and kidney disease, data in human models is lacking. The purpose of this
study is to determine if a low fructose intake could have an impact on the components of the
metabolic syndrome. The primary endpoint will be to determine the impact of low fructose on
weight loss. Secondary endpoints will evaluate the impact of low fructose diet on blood
pressure and cardiovascular biochemical profile.

If fructose is a causal pathway to obesity and metabolic syndrome, it may represent an
important target to mitigate this important health problem.

Inclusion Criteria:

- Individuals with a Body Mass Index (BMI) > 25. BMI defined as: Weight in kilograms
divided by Height (squared) in meters.

- Residents of Mexico city

- Healthy individuals (no comorbidities or drug prescription for associated chronic

Exclusion Criteria:

- Diabetes Mellitus Type 1 or 2

- Severe Hypertension (defined as systolic blood pressure > 160 mmHg and /or diastolic
blood pressure > 100 mmHg) and/or Hypertension on pharmacological treatment.

- Chronic Kidney Disease (Glomerular Filtration Rate (GFR) < 60 ml/min)

- Hepatic Damage or Advanced Disease (clinical, biochemical or histological)

- Patient receiving any pharmacological treatments for hypercholesterolemia and/or
elevated triglycerides.

- Anemia (any etiology)

- Malignancy

- Pregnancy

Type of Study:


Study Design:

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening

Outcome Measure:

Somatometry: including weight, height, Body Mass Index (BMI), % Body fat levels, waist and hip index, and blood pressure levels measurements performed by a single evaluator and calibrated equipment

Outcome Description:

measurements will be performed by a trained evaluator

Outcome Time Frame:

results obtained at the same day of evaluation (weekly monitoring during 6 weeks for each patient)

Safety Issue:


Principal Investigator

Magdalena Madero, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Instituto Nacional de Cardiología Ignacio Chávez


Mexico: National Institute of Public Health, Health Secretariat

Study ID:




Start Date:

March 2009

Completion Date:

February 2010

Related Keywords:

  • Overweight and Obesity
  • Metabolic Syndrome
  • Hyperuricemia
  • Role of Fructose in overweight and obesity
  • Fructose and metabolic syndrome
  • Low fructose diet study
  • Effects of fructose in blood pressure and hypertension
  • Somatometry changes observed in fructose diets
  • Fructose induced overweight and obesity
  • Fructose induced metabolic syndrome
  • Fructose induced hyperuricemia
  • Obesity
  • Overweight
  • Metabolic Syndrome X
  • Hyperuricemia